These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9160525)

  • 1. Augmentation of cell-mediated immunotherapy against herpes simplex virus by interleukins: comparison of in vivo effects of IL-2 and IL-7 on adoptively transferred T cells.
    Wiryana P; Bui T; Faltynek CR; Ho RJ
    Vaccine; 1997 Apr; 15(5):561-3. PubMed ID: 9160525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation of immunity to herpes simplex virus by in vivo administration of interleukin 2.
    Rouse BT; Miller LS; Turtinen L; Moore RN
    J Immunol; 1985 Feb; 134(2):926-30. PubMed ID: 2981270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
    Osorio Y; Ghiasi H
    J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes.
    Osorio Y; Ghiasi H
    J Virol; 2003 May; 77(10):5774-83. PubMed ID: 12719570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2 complex treatment amplifies CD8
    Rajasagi NK; Rouse BT
    Microbes Infect; 2016 Dec; 18(12):735-746. PubMed ID: 27866863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice.
    Cui FD; Asada H; Jin ML; Kishida T; Shin-Ya M; Nakaya T; Kita M; Ishii M; Iwai M; Okanoue T; Imanishi J; Mazda O
    Gene Ther; 2005 Jan; 12(2):160-8. PubMed ID: 15470476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An M2 Rather than a T
    Lee DH; Ghiasi H
    J Virol; 2018 May; 92(10):. PubMed ID: 29491152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic identification of antigen-dependent and antigen-independent CD8 CTL precursors in the draining lymph node during acute cutaneous herpes simplex virus type 1 infection.
    McNally JM; Dempsey D; Wolcott RM; Chervenak R; Jennings SR
    J Immunol; 1999 Jul; 163(2):675-81. PubMed ID: 10395657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection of BALB/c mice with a herpes simplex virus type 1 recombinant virus expressing IFN-gamma driven by the LAT promoter.
    Ghiasi H; Osorio Y; Hedvat Y; Perng GC; Nesburn AB; Wechsler SL
    Virology; 2002 Oct; 302(1):144-54. PubMed ID: 12429523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. II. Bifunctional clones with cytotoxic and virus-induced proliferative activities exhibit herpes simplex virus type 1 and 2 specific or type common reactivities.
    Yasukawa M; Zarling JM
    J Immunol; 1984 Nov; 133(5):2736-42. PubMed ID: 6207243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of interleukin-2 by a recombinant herpes simplex virus type 1 attenuates pathogenicity and enhances antiviral immunity.
    Ghiasi H; Osorio Y; Perng GC; Nesburn AB; Wechsler SL
    J Virol; 2002 Sep; 76(18):9069-78. PubMed ID: 12186890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection.
    Zhang X; Issagholian A; Berg EA; Fishman JB; Nesburn AB; BenMohamed L
    J Virol; 2005 Dec; 79(24):15289-301. PubMed ID: 16306600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes simplex virus type 1 (HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors for adoptive immunotherapy.
    Ma CK; Clancy L; Deo S; Blyth E; Micklethwaite KP; Gottlieb DJ
    Cytotherapy; 2017 Jan; 19(1):107-118. PubMed ID: 27793552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4-positive T lymphocytes are required for the generation of the primary but not the secondary CD8-positive cytolytic T lymphocyte response to herpes simplex virus in C57BL/6 mice.
    Jennings SR; Bonneau RH; Smith PM; Wolcott RM; Chervenak R
    Cell Immunol; 1991 Mar; 133(1):234-52. PubMed ID: 1671342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
    Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
    J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular interactions in the cytotoxic T lymphocyte response to herpes simplex virus antigens: differential antigen activation requirements for the helper T lymphocyte and cytotoxic T lymphocyte precursors.
    Schmid DS; Rouse BT
    J Immunol; 1983 Jul; 131(1):479-84. PubMed ID: 6223080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production.
    Mikloska Z; Rückholdt M; Ghadiminejad I; Dunckley H; Denis M; Cunningham AL
    J Immunol; 2000 May; 164(10):5167-76. PubMed ID: 10799875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes simplex virus-specific human cytotoxic T-cell colonies expressing either gamma delta or alpha beta T-cell receptor: role of accessory molecules on HLA-unrestricted killing of virus-infected targets.
    Maccario R; Comoli P; Percivalle E; Montagna D; Locatelli F; Gerna G
    Immunology; 1995 May; 85(1):49-56. PubMed ID: 7635521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
    Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
    Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.